2.2. Participants
liver dysfunctions, colorectal adenoma, inflammatory bowel disease, CRC, metabolic diseases, hypersensitivity, diabetes
GASTROINTESTINAL CANCERS, INFLAMMATORY BOWEL DISEASE, DISORDERS, METABOLIC DISEASES, HYPERSENSITIVITY, METASTASES, DIABETES
A randomized, single-blind, placebo-controlled prospective study was conducted at the Second Affiliated Hospital of Nanchang University, China, in the period from April 2021 to April 2022. All procedures were reviewed and approved by the Institutional Ethics Committee on medical research of this hospital. The study was also registered to the base of clinical trials, and the registration identifier was ChiCTR2000040916.A total of 100 patients diagnosed with CRC, satisfying the inclusion and exclusion criteria, were recruited finally. All participants signed the informed consents before enrolment, and their privacy was protected. The inclusion criteria included: (1) patients aged 40–70 years old with pathohistologically proven CRC, needing to undergo surgical resection and receive chemotherapy subsequently; (2) patients who did not have accompanying severe heart, lung, kidney, and liver dysfunctions and metabolic diseases; (3) patients with no distant metastases found. The exclusion criteria were as follows: (1) individuals had used antibiotics or consumed pro/pre/syn-biotic products within two weeks; (2) patients with metabolic diseases (e.g., diabetes and diabetes) and severe concomitant disorders in heart, lung, liver or kidneys; (3) patients with a history of inflammatory bowel disease and colorectal adenoma; (4) individuals with a family history of CRC and other gastrointestinal cancers; (5) other factors, such as hypersensitivity to study drugs and pregnant women.